Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

Breast Cancer Monthly Minutes

Use of chemotherapy near the end of life in patients with metastatic breast cancer may potentially negatively impact quality of life.
Low-dose tamoxifen could be used for prevention and to increase sensitivity of mammograms in premenopausal women.
Researchers report on early results from an effort to develop a predictive model and targeted strategies for communication and intervention for cancer screening during the COVID-19 pandemic.
Based on current drug pricing strategies in the United States, ribociclib combination therapy is unlikely to be cost-effective for treating postmenopausal patients with HR-positive HER2-negative advanced breast cancer.
For patients with recurrent metastatic HER2-positive breast cancer, new therapies such as margetuximab will expand treatment options.
To help inform treatment decision-making, guidelines have been developed on surveillance mammography for early breast cancer survivors who are ≥75 years of age.
Patients reported satisfaction with nurse-led telephone end-of-treatment follow-up experiences; therefore, permanent modifications may be warranted.
Breast cancer survival disparities persist even after adjusting for sociodemographic factors, tumor characteristics, and NCCN guideline–appropriate treatment, suggesting that social and environmental factors can impact survival.
Interfacility variation in efforts to eliminate the use of unnecessary breast cancer procedures highlights the need for more formalized deimplementation plans.
Page 1 of 2
Results 1 - 10 of 15